ADIOS: Antibody Development via Opponent Shaping

Introduction to the show: ident: AI Radio. Generated commentary on the latest Artificial Intelligence papers.

Tom: Next we'll be talking about the paper "ADIOS: Antibody Development via Opponent Shaping".

Jane: The paper was written by Sebastian Towers, Aleksandra Kalisz, Philippe A. Robert, Alicia Higueruelo, Francesca Vianello et al. from University of Oxford and University of Basel and Isomorphic Labs and Exscientia and Epsilogen Ltd..

Tom: Stay tuned as we take you through the paper and discuss its implications.

Title: Tom: Welcome back to the show, everybody. Today we're looking at a paper that's got a fantastic acronym — ADIOS: Antibody Development via Opponent Shaping. Jane, I have to say, the title alone made me sit up.

Jane: It grabbed me too, Tom. And the name is actually perfect once you understand what they're doing. "Opponent shaping" comes from game theory and multi-agent AI — it's about influencing how your opponent learns and evolves, not just beating them at the current moment.

Tom: So instead of designing an antibody that just works against today's virus, they're designing one that actually steers how the virus mutates in the future. That's a wild idea.

Jane: Exactly. And that's why the title matters. ADIOS isn't just a catchy name — it's literally describing the method. The antibody is saying "adios" to the virus's ability to escape over time.

Tom: And I love that they frame it as a two-player game. The virus wants to evade the antibody, the antibody wants to bind to the virus. But the clever twist is that the antibody's moves today change what the virus learns tomorrow.

Jane: Right. And that's the "opponent shaping" part. Most therapy design is myopic — you target the current strain, and then you're surprised when the virus evolves resistance. ADIOS says, let's anticipate that evolution and push it in a direction we want.

Tom: So the title is really a promise. It's saying we're not just developing antibodies, we're developing antibodies that shape the opponent's future behavior.

Jane: And that's a fundamentally different way of thinking about medicine. It's not just "hit the target" — it's "make the target evolve into something weaker."

Tom: I'm already hooked. Let's get into what they actually did.

Summary: Jane: So Tom, let's break down what this paper actually does. They built a framework where you have two nested loops. The inner loop simulates the virus evolving to escape a given antibody. The outer loop optimizes the antibody to perform well across those simulated escape trajectories.

Tom: So it's like a training simulator for antibodies. You let the virus "practice" escaping, and then you pick the antibody that survives the longest.

Jane: Exactly. And the key insight is that the antibody's fitness isn't just about binding strength to the current virus. It's about the average payoff across a whole trajectory of viral mutations.

Tom: And they use this thing called Absolut! to simulate binding — it's a protein interaction simulator. But here's the kicker — they reimplemented it in JAX and got a ten-thousand-fold speedup.

Jane: That's huge. Because to do this opponent shaping, you need to run thousands of viral escape simulations, and each one requires millions of binding calculations. Without that speedup, the whole approach would be computationally impossible.

Tom: Right. And they tested it on the dengue virus, but also on West Nile, influenza, MERS-CoV, and even a bacterium. In every case, the "shaper" antibodies outperformed the myopic ones on the long-term objective.

Jane: And the really cool part — they showed that the shapers don't just resist escape. They actively shape the virus's evolution so that the final variants are more vulnerable to other antibodies too.

Tom: So it's not just "my antibody is better." It's "my antibody makes the virus weaker in general." That's a game-changer.

Jane: It really is. And it's worth emphasizing — the paper is a proof of concept. The binding simulator is simplified. But the framework is the contribution, and it's designed to work with better simulators as they come along.

Tom: So the summary is: they've shown that thinking about viral evolution as an opponent you can shape, rather than a static target, leads to fundamentally better therapies.

Improvements: Tom: So Jane, what does this paper actually improve upon? I mean, antibody design has been around for a while.

Jane: Right, and that's the key point. Most existing antibody design methods optimize for binding to a known antigen structure. They use energy-based methods, language models, graph neural networks — all trying to find the antibody that binds best to the current virus.

Tom: And that's the myopic approach.

Jane: Exactly. And there's also work on predicting viral escape — like EVEscape, which tries to forecast which mutations will emerge. But those methods treat the antibody as a fixed pressure. They don't ask "how should the antibody change to make escape harder?"

Tom: So ADIOS is the first to connect those two things — predicting escape and optimizing the antibody — into a single loop.

Jane: Precisely. And that's the improvement. They're not just saying "here's a better binding predictor." They're saying "here's a new objective function for antibody design that accounts for the virus's adaptive response."

Tom: And the results back it up. The shapers with horizon one hundred significantly outperformed myopic antibodies on the escape-averaged fitness. But I noticed there's a trade-off — the shapers actually did worse on immediate binding.

Jane: That's a really important finding. The shapers sacrifice some immediate potency for long-term robustness. And the paper even shows that the optimal training horizon depends on your compute budget. If you're limited, a shorter horizon like twenty can be a better proxy than one hundred.

Tom: So it's not just "bigger horizon is always better." It's about matching the horizon to your resources.

Jane: Right. And they also showed that the shaping effect persists even when there's external pressure from other antibodies — which is more realistic, because in real life you might have multiple therapies circulating.

Tom: So the improvement is really about the mindset. Instead of asking "what binds best today," you ask "what makes the virus evolve into something we can handle tomorrow."

Conclusion: Tom: Alright, let's wrap this up. We've been talking about ADIOS: Antibody Development via Opponent Shaping, and I think it's fair to say this is one of those papers that makes you see a whole field differently.

Jane: Absolutely. The core idea is simple but profound — treat the virus as an adaptive opponent, not a static target. And then optimize your therapy to shape that opponent's evolution, not just to beat its current form.

Tom: And the practical implications are enormous. Think about COVID — we saw vaccines lose effectiveness against new variants. ADIOS offers a path toward therapies that don't just fight today's strain but actively steer the virus toward weakness.

Jane: And it's not just viruses. The paper mentions cancer — monoclonal antibodies for tumors. Cancer cells evolve resistance too. The same opponent shaping principle could apply there.

Tom: And antimicrobial resistance — bacteria evolving to escape antibiotics. Same problem, same potential solution.

Jane: Right. Now, we should be clear — this is a proof of concept with a simplified simulator. You can't go out and design a real drug with this yet. But the framework is designed to plug in better simulators, like AlphaFold3, as they become available.

Tom: So it's a foundation. A new way of thinking about therapy design that could eventually lead to longer-lived vaccines and treatments.

Jane: And that's why we're excited. It's not just a better algorithm — it's a better question to ask. And sometimes, asking the right question is the biggest step forward.

Tom: Well said, Jane. That's a wrap on ADIOS. Thanks to everyone for listening, and we'll see you on the next one.

Jane: Goodbye, everyone!